18. Zimmer Biomet
Revenue: $7,982,200,000*
Warsaw, Ind.
2019 rank: 18
R&D spend: $449,300,000
Employees: 19,900
*Fiscal year ended 12/31/2019
Like most in the implant space, orthopedic device giant Zimmer Biomet felt the impact of COVID-19 and the deferral of elective procedures in the early days of the pandemic. The company lost $509 million in the first quarter and, while it made a recovery to profits of $246.1 million in the third quarter, uncertainties remain as the pandemic roars on. “While the stronger-than-expected recovery of elective procedures in the third quarter was encouraging, we also remain focused on ZB’s strong operational execution, which continues to drive confidence in our underlying business,” Zimmer Biomet president & CEO Bryan Hanson said after the third quarter. “It is important to note that the challenges and fluidity around COVID-19 persist as we move into the end of the year. Still, we will continue to transform our business, invest for greater value and prioritize innovation to better position the company for accelerated growth over the long term.” — SW
Key personnel: Bryan Hanson, president & CEO; Didier Deltort, president, EMEA; Rachel Ellingson, SVP & chief strategy officer; David Kunz, SVP, global quality & regulatory affairs; Angela Main, SVP, global chief compliance officer & associate general counsel, Asia Pacific; Keri Mattox, SVP, investor relations & chief communications officer; Carrie Nichol, VP, controller & chief accounting officer; Chad Phipps, SVP, general counsel & secretary; Pamela Puryear, SVP, chief human resources officer; Zeeshan Tariq, VP & chief information officer; Ivan Tornos, group president, global businesses and the Americas; Kenneth Tripp, SVP, global operations & logistics; Suketu Upadhyay, EVP & CFO; Sang Yi, president, Asia Pacific